In addition, more patients in our study had high grade disease (50%), ER-negative disease (41%) and HER2-positive disease (38%), while in the Finnish study only 30% were diagnosed with high grade breast cancer, 31% had ER-negative disease and 18% had HER2 amplification. This evidence concerns the gene ERBB2 and breast carcinoma.